A formula milk powder and a method of making the same

Abstract

The application provides a formula milk powder and a preparation method thereof. The preparation raw materials of the formula milk powder include 0-4.5 parts of breast milk oligosaccharide, 890-3800 parts by weight of raw cow milk, 0-480 parts by weight of lactose, 0-540 parts by weight of desalted whey powder, 0-350 parts by weight of skimmed milk powder, 0-80 parts by weight of whey protein powder WPC80, 0-120 parts by weight of whey protein powder WPC34, 0-225 parts of vegetable oil, 0-45 parts by weight of alpha-lactalbumin, 0-23 parts by weight of beta-casein, 1-2.5 parts by weight of phospholipid, 0-30 parts by weight of fructooligosaccharide, 0-90 parts by weight of galactooligosaccharide syrup, 0-0.18 parts by weight of probiotics, 0-5 parts by weight of anhydrous butter, 0-0.8 parts by weight of nucleotide, 1-5 parts by weight of vitamin nutrients and the like. The formula milk powder provided by the application provides a solution for improving the intestinal microenvironment health, such as reducing hydrogen sulfide.

Description

[0001] This application is a divisional application of application number 202211529126.9, filed on November 30, 2022, entitled "A Formula Milk Powder and Its Preparation Method". Technical Field

[0002] This invention relates to the field of dairy products, specifically to a formula milk powder and its preparation method. Background Technology

[0003] Human milk oligosaccharides are approximately 12-14 g / L in mature milk and approximately 20-24 g / L in colostrum. Human milk oligosaccharides are mainly composed of three categories: (1) fucoidan oligosaccharides, with 2'-fucosyl oligosaccharides and 3-fucosyl oligosaccharides as representative substances; (2) sialic acid oligosaccharides, with 3'-sialic acid lactose and 6'-sialic acid lactose as representative substances; and (3) oligosaccharides formed by core sugar chains without fucoidan or sialic acid groups, with lactose-N-tetrasaccharide (LNT) and lactose-N-neotetrasaccharide (LNnT) as representative substances.

[0004] As the three main functions of human milk oligosaccharides have been gradually reported and discovered: (1) inhibiting the attachment and infection of specific pathogens; (2) acting as a prebiotic to promote the growth of bacteria in the intestinal symbiotic system; and (3) directly reducing the inflammatory response of the mucosa under toxic stimulation, the presence and content of human milk oligosaccharides vary among individuals and are related to the Lewis secretory composition of lactating mothers.

[0005] Lactose-N-neotetrasaccharide (LNnT) is one of the most abundant neutral-chain core oligosaccharides in breast milk. It is a tetrasaccharide composed of two D-galactoses, one N-acetyl-D-glucosamine, and one D-glucose. Currently, commercially available LNnT is prepared by microbial fermentation, and its structure has been confirmed by mass spectrometry and nuclear magnetic resonance to be identical to that of oligosaccharides found in human milk.

[0006] Human milk oligosaccharides can be considered a microecological management tool for improving bodily health, as they can alter, regulate, and reorganize existing gut microbiota. Anaerobic bacilli, bifidobacteria, eubacteria, streptococci, and lactobacilli in the gut microbiota can release short-chain fatty acids, mainly including acetic acid, propionic acid, butyric acid, and valeric acid, through the fermentation of carbohydrates, proteins, and lipids.

[0007] The gut microbiota of infants also ferments and produces gases such as carbon dioxide and methane, leading to symptoms such as bloating and flatulence. Furthermore, during the degradation of the intestinal mucosa, harmful bacteria can invade the intestinal mucosa, and mucopolysaccharides can be rapidly degraded into thiosulfate and free sulfate ions through intermediate reactions, ultimately producing the toxic gas hydrogen sulfide. In inflammatory responses, intestinal homeostasis is disrupted, thiosulfate can be oxidized to tetrathionate, and this promotes further invasion by harmful bacteria such as Salmonella. Under these conditions, the integrity of the intestinal wall is compromised, and leaky gut symptoms can lead to a reduction in the production of short-chain fatty acids. Currently, in the fields of infant formula, complementary foods, and nutritional supplements, the human milk oligosaccharides provided by this invention and their compositions with probiotics offer a solution to improve gut microenvironment health, such as reducing the production of the toxic gas hydrogen sulfide. Summary of the Invention

[0008] One object of the present invention is to provide a formula milk powder.

[0009] Another object of the present invention is to provide a method for preparing the formula milk powder.

[0010] To achieve the above objectives, in one aspect, the present invention provides a formula milk powder, wherein, based on a total weight of 1000 parts, the raw materials for preparing the formula milk powder include: 0-4.5 parts of human milk oligosaccharides (HMOs), 890-3800 parts by weight of raw milk, 0-480 parts by weight of lactose, 0-540 parts by weight of demineralized whey powder, 0-350 parts by weight of skim milk powder, 0-80 parts by weight of whey protein powder (WPC80), and whey protein powder (WPC34). 0-120 parts by weight, vegetable oil 0-225 parts, α-lactalbumin 0-45 parts by weight, β-casein 0-23 parts by weight, phospholipids 1-2.5 parts by weight, fructooligosaccharides (fructooligosaccharide powder) 0-30 parts by weight, galactooligosaccharide syrup 0-90 parts by weight, probiotics 0-0.18 parts by weight, anhydrous butter 0-5 parts by weight, nucleotides 0-0.8 parts by weight, vitamin nutrients 1-5 parts by weight, choline chloride 0-3 parts by weight, mineral A 0-2 parts by weight, mineral B 1-12 parts by weight; wherein, mineral A is selected from one or more mineral salts selected from copper, iron, magnesium, zinc, selenium, manganese and iodine, and mineral B is selected from one or more mineral salts selected from calcium, phosphorus, sodium and potassium.

[0011] According to some specific embodiments of the present invention, the human milk oligosaccharide contains human milk oligosaccharide LNnT, and the human milk oligosaccharide LNnT is 0.01-4.5 parts by weight.

[0012] According to some specific embodiments of the present invention, the vegetable oil is selected from one or more combinations of structured oil OPO, high oleic sunflower seed oil, corn oil, low erucic acid rapeseed oil and soybean oil; when each vegetable oil component exists independently, based on a total weight of 1000 parts of formula milk powder, the amounts of each vegetable oil component are as follows: structured oil OPO 0~170 parts by weight, high oleic sunflower seed oil 0~150 parts by weight, corn oil 0~50 parts by weight, low erucic acid rapeseed oil 0~50 parts by weight, and soybean oil 0~80 parts by weight.

[0013] According to some specific embodiments of the present invention, the vitamin nutrients are selected from one or more combinations of vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, folic acid, pantothenic acid and biotin.

[0014] The vitamins and minerals in the formula of this invention can be a compound nutrient composition that meets national standards. Different amounts can be added according to different formulas, and the specific addition method can refer to the conventional operation in the relevant field.

[0015] Preferably, the formula milk powder of the present invention may selectively use any or any combination of the following compound nutrient components if compound nutrients are added as needed (content per gram; the amount of each indicator is calculated based on the median value of the addition range; there is basically no situation where the content of all indicators is at its maximum at the same time):

[0016] Vitamin A: 1300~4000μgRE

[0017] Vitamin D: 24~60μg

[0018] Vitamin E: 13~41mg α-TE

[0019] Vitamin K1: 200~550μg

[0020] Vitamin B1: 2600~6500μg

[0021] Vitamin B2: 600~3000μg

[0022] Vitamin B6: 1200~4000μg

[0023] Vitamin B12: 2~14.0μg

[0024] Nicotinamide: 12000~30000μg

[0025] Folic acid: 300~653μg

[0026] Pantothenic acid: 8750~16230μg

[0027] Biotin: 56~150μg.

[0028] According to some specific embodiments of the present invention, the mineral content (content per gram) is:

[0029] Sodium: 30~400mg

[0030] Potassium: 63~400mg

[0031] Copper: 2200~5540μg

[0032] Magnesium: 133~400mg

[0033] Iron: 23~95mg

[0034] Zinc: 25~52mg

[0035] Calcium: 110~300mg

[0036] Phosphorus: 75~200mg

[0037] Iodine: 200~1592μg

[0038] Selenium: 16~48μg

[0039] Manganese: 16~547μg.

[0040] According to some specific embodiments of the present invention, the probiotics are selected from one or more combinations of Bifidobacterium animalis subsp. lactis BB-12, Bifidobacterium infantis YLGB-1496, Bifidobacterium animalis subsp. lactis HN019 and Bifidobacterium lactis BL-99.

[0041] According to some specific embodiments of the present invention, the Bifidobacterium infantis YLGB-1496 is a Bifidobacterium infantis with accession number CGMCC No.21109.

[0042] According to some specific embodiments of the present invention, the Bifidobacterium lactis BL-99 is a Bifidobacterium lactis with accession number CGMCC No. 15650.

[0043] According to some specific embodiments of the present invention, the probiotic is Bifidobacterium lactis BL-99.

[0044] According to some specific embodiments of the present invention, the formula milk powder contains human milk oligosaccharide LNnT, and the content of human milk oligosaccharide LNnT per 100g formula milk powder is 142.9-428.6 mg / 100g powder; preferably 178.6-392.9 mg / 100g powder.

[0045] According to some specific embodiments of the present invention, the formula milk powder contains probiotics, and the probiotic content is 10 per gram of formula milk powder. 6 -2×10 12 CFU; preferably 10 8 -2×10 10 CFU.

[0046] According to some specific embodiments of the present invention, the formula milk powder further includes the following components: 0.20~2.04 parts by weight of inositol, 0~0.65 parts by weight of taurine, 0.06~0.5 parts by weight of L-carnitine, 3~18 parts by weight of DHA, and 3~22 parts by weight of ARA.

[0047] According to some specific embodiments of the present invention, the formula milk powder is an infant formula milk powder used to reduce hydrogen sulfide in the intestines of infants.

[0048] According to a specific embodiment of the present invention, the infant formula milk powder of the present invention can be either infant formula milk powder or toddler formula milk powder.

[0049] According to a specific embodiment of the present invention, the infant formula milk powder of the present invention may include conventional components of infant formula milk powder in addition to the lactobacillus and human milk oligosaccharides.

[0050] In the formula milk powder of the present invention, the protein and fat of raw milk can be replaced by whole milk powder and / or skim milk powder; whey protein powder WPC80 and whey protein powder WPC34 can be partially replaced by α-lactalbumin.

[0051] On the other hand, the present invention also provides a method for preparing the formula milk powder, the method comprising: wet mixing – homogenization – concentration and sterilization – spray drying – dry mixing – packaging.

[0052] According to some specific embodiments of the present invention, the wet mixing process includes homogenizing and sterilizing raw milk, and then sequentially adding powdered raw materials, oily raw materials, vitamin nutrients, mineral raw materials and human milk oligosaccharides to obtain a mixed liquid; the powdered raw materials are other solid raw materials other than human milk oligosaccharides, vitamin nutrients and mineral raw materials.

[0053] According to some specific embodiments of the present invention, the wet batching process includes the following steps:

[0054] 1) Coarse filtration of milk: After filtering and degassing, raw milk is preheated and then separated by a separator to remove impurities;

[0055] 2) Homogenization and sterilization of milk: After removing impurities, part of the raw milk is homogenized in a homogenizer, while the other part is not homogenized. The two are then mixed and sterilized in a mixing tank after homogenization.

[0056] 3) Adding powders: Add various powder ingredients to the mixing tank according to the formula;

[0057] 4) Melting and blending oils: After melting the oily raw materials, add them to the mixing tank;

[0058] 5) Nutrient dissolution and addition: Dissolve vitamin nutrients and mineral raw materials separately in purified water, and then add them to the mixing tank in sequence to obtain a mixed liquid.

[0059] 6) LNnT dissolution and addition: Dissolve part of the LNnT raw material in the mixture solution in step 5), and add it to the mixing tank to obtain a mixture solution containing LNnT.

[0060] According to some specific embodiments of the present invention, the wet batching process includes the following steps:

[0061] 1) Coarse filtration of milk: After coarse filtration and degassing in a balance cylinder, the milk is preheated by a plate heat exchanger and then separated by a separator to remove impurities.

[0062] 2) Homogenization and sterilization of milk: After removing impurities, part of the raw milk is homogenized in a homogenizer, while the other part is not homogenized. The two are then mixed and put into the sterilization system for sterilization.

[0063] 3) Powder addition: Various powder raw materials are metered according to the formula and then added to the powder mixing tank through the pneumatic conveying system, and then sucked into the mixing tank through the vacuum system;

[0064] 4) Melting and blending oil: According to the formula requirements, put the oil and fat raw materials specified in the formula into the melting room. The temperature of the melting room is maintained at 50~90℃. After the oil is melted, it is pumped into the mixed oil storage tank, and the mixed oil is pumped into the mixing tank through the oil pump according to the formula requirements.

[0065] 5) Nutrient dissolution and addition: Dissolve vitamin nutrients and mineral raw materials separately in purified water, and then add them to the mixing tank in sequence to obtain a mixed liquid.

[0066] 6) LNnT dissolution and addition: Dissolve part of the LNnT raw material in the mixture solution in step 5), and add it to the mixing tank to obtain a mixture solution containing LNnT.

[0067] According to some specific embodiments of the present invention, the method further includes a step of filtering the obtained LNnT-containing mixture.

[0068] According to some specific embodiments of the present invention, the homogenization includes homogenizing the obtained LNnT-containing mixture using a homogenizer.

[0069] According to some specific embodiments of the present invention, the homogenization further includes cooling the homogenized mixture to below 20°C.

[0070] According to some specific embodiments of the present invention, the concentration sterilization includes sterilizing the obtained LNnT-containing mixture (preferably a homogenized mixture or a cooled mixture) at a temperature of not less than 83°C for 25 seconds to obtain a concentrated sterilized milk.

[0071] According to some specific embodiments of the present invention, the concentration and sterilization includes performing double-effect concentration on the obtained LNnT-containing mixed liquid (preferably homogenized mixed liquid or cooled mixed liquid) and sterilizing at not less than 83°C for 25 seconds to obtain concentrated and sterilized milk.

[0072] According to some specific embodiments of the present invention, the parameters of the spray drying include: inlet air temperature 170-190℃, outlet air temperature 80-90℃, pump pressure 150-250 bar, and negative pressure -4.5 to -3.5 mba.

[0073] According to some specific embodiments of the present invention, the parameters of the spray drying include: inlet air temperature 180°C, outlet air temperature 86°C, pump pressure 200 bar, and negative pressure -4.0 mba.

[0074] According to some specific embodiments of the present invention, the spray drying is carried out using a drying tower.

[0075] According to some specific embodiments of the present invention, the high-pressure pump pressure is 150-250 bar (preferably 200 bar), and the tower negative pressure is -4.5 to -3.5 mba (preferably -4.0 mba).

[0076] According to some specific embodiments of the present invention, the spray drying includes preheating the concentrated and sterilized milk to 50-70°C (preferably 60-65°C), filtering it (preferably using a filter with a pore size of 1-2 mm), and then spray drying it.

[0077] According to some specific embodiments of the present invention, the spray drying further includes a secondary drying (preferably using a fluidized bed) after spray drying, followed by cooling to 25-35°C (preferably 30°C).

[0078] According to some specific embodiments of the present invention, the dry mixing process includes uniformly mixing DHA and ARA with milk powder obtained after spray drying.

[0079] In summary, this invention provides a formula milk powder and its preparation method. The formula milk powder of this invention has the following advantages:

[0080] The formula milk powder provided by this invention offers a solution for improving gut microenvironment health, such as reducing hydrogen sulfide. Simultaneously, the combination of LNnT and probiotics provided by this invention is applied in the preparation of foods for reducing hydrogen sulfide in the gut. The breast milk-based infant formula milk powder of this invention, containing LNnT and probiotics (Bifidobacterium lactis BL-99), has the effect of reducing hydrogen sulfide in the gut. Attached Figure Description

[0081] Figure 1 The results of small-batch fermentation of LNnT and probiotics to produce total short-chain fatty acids were obtained to simulate the intestinal environment of infants.

[0082] Figure 2 The results show the percentage of hydrogen sulfide produced during small-batch fermentation of LNnT and probiotics in a simulated infant gut environment. Detailed Implementation

[0083] The following detailed embodiments illustrate the implementation process and beneficial effects of the present invention, aiming to help readers better understand the essence and characteristics of the present invention, and are not intended to limit the scope of implementation of this case.

[0084] Experimental methods

[0085] The specific methods for determining the gas pressure, gas composition, and short-chain fatty acid content of the fermented products of a sample include:

[0086] First, sample collection was conducted: stool samples were collected from infants aged 3-6 months who were breastfed or formula-fed. During this age range, one oral swab, one sample of fresh breast milk, and one corresponding infant stool sample were collected from each mother in the breastfed group; one stool sample was collected from each infant in the formula-fed group. Fresh stool samples were obtained from donors, transported to the laboratory within 4 hours using ice packs, fermented, and the short-chain fatty acids in the fermentation products were measured.

[0087] The measurement process is as follows:

[0088] 1. Culture medium preparation

[0089] (1) Prepare YCFA anaerobic basic culture medium, and dispense 30ml into anaerobic vials with a total volume of 50ml for later use.

[0090] The YCFA anaerobic basal medium formula is as follows (g / L): tryptone 10, yeast extract 2.5, L-cysteine ​​hydrochloride 1, NaCl 0.9, CaCl2·6H2O 0.009, KH2PO4 0.45, K2HPO4 0.45, MgSO4·7H2O 0.09;

[0091] It also includes the following ingredients: 1 mL of resazurin (1 mg / mL), 2 mL of heme (5 mg / mL), and 200 μl of vitamin I solution;

[0092] The vitamin I solution contains (mg / mL): biotin (VH) 0.05, cobalamin (VB12) 0.05, para-aminobenzoic acid 0.15, folic acid 0.25, and pyridoxine (VB6) 0.75.

[0093] (2) Prepare the culture medium required for the embodiments of the present invention.

[0094] Before the fermentation experiment, probiotics or prebiotics were added to the YCFA medium as needed to prepare the medium required for this project. The final concentration of prebiotics added in this experiment was 4‰; the final concentration of each probiotic added was 10‰. 9 CFU / mL.

[0095] The probiotics and prebiotics added in the experiment are shown in Table 1. Each culture medium was divided into two cases: with and without ETEC, totaling 42 fermentation conditions. The final concentration of added ETEC was 10. 10 CFU / mL.

[0096] Table 1 Fermentation Conditions List

[0097]

[0098] 2. Strain activation and identification

[0099] Bacterial powders of strains BB12, YLGB-1496, HN019, and BL-99 were respectively prepared to a final concentration of 10 μL in an anaerobic workstation. 7 CFU / mL, concentration was determined using plate count method. Before preparing the culture medium, the glycerol tube inoculum preserved at -80℃ was taken out and inoculated into MRS medium for activation. Then, the activated bacterial solution was inoculated into the corresponding culture medium using a syringe.

[0100] Take ETEC (ATCC35401) bacterial powder and prepare it to 10 in the anaerobic workstation. 10 The concentration was determined using the plate count method at CFU / mL.

[0101] 3. In vitro fermentation

[0102] (1) Preparation of samples before fermentation:

[0103] Accurately weigh 0.800±0.010g of fresh feces and place it on one side of the stirring spoon of the feces pretreatment box. Calculate and add the corresponding volume of PBS buffer according to a 10% (w / v) ratio. Vortex for approximately 5-10 minutes to thoroughly disperse the fecal residue and mix evenly with the PBS buffer to prepare a homogeneous 10% fecal suspension. Place the feces pretreatment box on a table and filter the suspension through two layers of filters for later use.

[0104] (2) Inoculation: In the anaerobic workstation, use a 1mL syringe with a No. 5 needle to draw 0.5mL of the suspension (the clear side in the pretreatment box), puncture the butyl rubber stopper of the vial, and inject the culture medium. If gas production analysis is required, use a barometer to detect and record the gas pressure after 0 hours of fermentation.

[0105] Inoculation and dynamic sampling were both completed in an anaerobic workstation. Five biological replicates were set up for each culture medium in both the breastfed and formula-fed groups.

[0106] The remaining original fecal samples and fecal suspensions can be aliquoted as needed, labeled, and frozen for later testing. When reusing, thaw the fecal samples within 30 minutes, gently mix them with the culture medium, and add them to the batch fermentation medium as the initial culture medium. Continue mixing to maintain ideal homogeneity. Because the thawing time is consistent, the initial bacterial composition of each group is similar.

[0107] (3) Fermentation: Place the vial in a 37°C incubator and incubate for 24 hours without disturbing it. After the incubation is complete, remove the vial, do not open the cap, and freeze it directly at -20°C for testing.

[0108] 4. Gas detection

[0109] Remove the fermentation vial, use a barometer to measure and record the gas pressure at the fermentation endpoint (24 hours), and use a gas analyzer (HL-QT01, Hunan Hailu Biotechnology Co., Ltd.) to detect the gas composition.

[0110] Specifically, the instrument consists of a gas sampler, a valve module, a vacuum generator, and a gas detection chamber integrating multiple gas sensors. The gas distribution module uses the vacuum generator to control the amount of gas introduced into the gas detection chamber. The detection steps are as follows:

[0111] ① Detect the gas in the blank culture medium and calibrate the instrument;

[0112] ②The gas detection chamber is adjusted to a certain vacuum level using a vacuum generator via a gas distribution module;

[0113] ③ The gas in the vial is drawn into the instrument's detection chamber using a gas sampler, and the gas volume is adjusted using a gas mixing module;

[0114] ④ Use the corresponding gas sensors to detect the four gases CO2, H2, CH4, and H2S entering the gas detection chamber;

[0115] ⑤ Calculate the gas ratio using pre-set software.

[0116] 5. Detection of short-chain fatty acids

[0117] The total concentration of short-chain fatty acids, including acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid, was detected using a gas chromatograph (9720, Zhejiang Fuli Analytical Instrument Co., Ltd.). The specific steps are as follows:

[0118] (1) Preparation before sample injection: Use a sterile needle to draw 500 μL of fermentation broth into a 1.5 ml centrifuge tube, add 100 μL of crotonic acid metaphosphate solution, and freeze at -30℃ for 24 h. After thawing, centrifuge at 10000 rpm and 4℃ for 3 min, collect the supernatant, and filter it through a 0.22 μm filter (Millipore). Take 100 μL of sample extract and add it to the inner tube of the gas chromatograph sample bottle. After sealing the tube tightly to remove air bubbles, load the sample for analysis.

[0119] (2) The gas chromatography instrument conditions are as follows:

[0120] Column: Agilent FFAP 30 m × 0.25 mm × 0.25 μm; Column temperature: 75℃, ramped up to 180℃ at 20℃ / min and held for 1 min, ramped up to 220℃ at 50℃ / min and held for 1 min;

[0121] Injector: Temperature: 250℃, Injection volume: 1.0μL, Split ratio: (5:1); Carrier gas: High-purity nitrogen; Flow rate: 2.5 mL / min for 6.5 min, 2.8 mL / min to 2.8 mL / min for 2 min;

[0122] Detector: FID; Temperature: 250℃; Purging: 20mL / min; Hydrogen: 30mL / min; Air: 300mL / min.

[0123] (3) Quantitative determination is performed using the peak area internal standard method, and the internal standard method is automatically calculated using the built-in software of the workstation according to the standard curve equation.

[0124] Example 1

[0125] This embodiment provides a small-batch fermentation of LNnT and probiotics in a simulated infant gut environment to produce total short-chain fatty acids. Results are shown below. Figure 1 As shown.

[0126] It can be seen that in all experimental groups, the combination of LNnT and probiotics was superior to the blank control and the four probiotics acting alone.

[0127] Further inter-group comparisons were conducted on the combinations of LNnT with different probiotics, and the results are shown in Table 2. Table 2 shows that in the absence of ETEC, the total acid production of all four combinations in the formula was higher than that in the breast milk group (P<0.05). Among them, LNnT and BL-99, even with ETEC, still produced more short-chain fatty acids in the formula than the breast milk group, indicating that they contribute to establishing a healthier gut environment (P=0.0229).

[0128] Table 2

[0129]

[0130] Example 2

[0131] This embodiment provides the results of the percentage of hydrogen sulfide produced by a small-batch fermentation of LNnT and probiotics in a simulated infant gut environment.

[0132] The results of small-batch fermentation of LNnT combined with probiotics in a simulated infant gut environment, showing the percentage of hydrogen sulfide produced as a percentage of total gas production, are shown below. Figure 2 As shown. By Figure 2 It can be seen that in all experimental groups, the combination of LNnT and probiotics was superior to the blank control and the four probiotics alone control groups.

[0133] Further comparisons of the results across different groups are shown in Table 3. Table 3 shows that, with or without ETEC, formula-fed infants produced more hydrogen sulfide in their stool compared to the breastfed group. The presence or absence of ETEC showed a significant difference in the breastfed group, but not in the formula-fed group. This indicates that ETEC is not a major factor affecting hydrogen sulfide production in formula-fed infants; conversely, the presence of ETEC may lead to increased hydrogen sulfide gas production in breastfed infants.

[0134] Table 3

[0135]

[0136] Further comparison of the breast milk without ETEC group revealed that the hydrogen sulfide produced by the LNnT+BL-99 combination was lower than that produced by the LNnT monomer (P<0.05). While there was no significant difference between LNnT+BB12 and LNnT+YLGB-1496 and LNnT, there was a significant trend (P<0.1), indicating that the above combinations of LNnT and probiotics can produce a synergistic effect. The comparison results are shown in Table 4.

[0137] Table 4

[0138]

[0139] For the ETEC group in breast milk, no significant differences in hydrogen sulfide production were observed under different fermentation conditions. The comparison results are shown in Table 5.

[0140] Table 5

[0141]

[0142] In the ETEC-free formulation group, LNnT+YLGB-1496 and LNnT+BL-99 produced less hydrogen sulfide than LNnT (P<0.05). While there was no significant difference between LNnT+BB12 and LNnT+HN019 and LNnT, there was a significant trend (P<0.1), indicating that the combination of LNnT with probiotics can synergistically enhance the effect and further reduce hydrogen sulfide production. See Table 6 for comparison results.

[0143] Table 6

[0144]

[0145] In the ETEC-containing formulation group, no significant differences were observed in hydrogen sulfide production under different fermentation conditions, as shown in Table 7.

[0146] Table 7

[0147]

[0148] Example 3

[0149] Infant formula milk powder containing a combination of LNnT and probiotics 1 (preparation of 1000 kg):

[0150] 3100 kg raw milk, 300 kg lactose, 25 kg whey protein powder (WPC 80%), 100 kg demineralized whey powder (D90), 72 kg OPO structured lipids, 54 kg soybean oil, 9 kg corn oil, 45 kg high-oleic sunflower oil, 27 kg α-lactalbumin powder, 9 kg β-casein powder, 1 kg anhydrous butter, 25 kg fructooligosaccharide powder, 40 kg galactooligosaccharide syrup, 2 kg soybean lecithin, 2.5 kg human milk oligosaccharide (LNnT), 17.85 kg compound nutrients, 12 kg DHA, 22 kg ARA, 0.15 kg Bifidobacterium lactis BL-99.

[0151] The compound nutrients include approximately 3.5 kg of compound vitamin nutrient pack, approximately 1.5 kg of choline chloride nutrient pack, approximately 11 kg of calcium powder nutrient pack, approximately 1 kg of mineral nutrient pack, and approximately 0.85 kg of magnesium chloride nutrient pack. The base material for each nutrient pack is lactose.

[0152] Infant formula milk powder containing a combination of LNnT and probiotics 2 (preparation of 1000 kg):

[0153] 1000 kg raw milk, 250 kg skim milk powder, 150 kg lactose, 50 kg whey protein powder (WPC 34%), 225 kg demineralized whey powder (D90), 106 kg OPO structured lipids, 37 kg soybean oil, 30 kg corn oil, 10 kg α-lactalbumin powder, 10 kg β-casein powder, 5 kg fructooligosaccharide powder, 15 kg galactooligosaccharide syrup, 3.5 kg human milk oligosaccharide (LNnT), 11 kg compound nutrients, 12 kg DHA, 14 kg ARA, 0.25 kg Bifidobacterium lactis BL-99, and 0.65 kg nucleotides.

[0154] The compound nutrients include approximately 1.5 kg of compound vitamin nutrient pack, approximately 0.75 kg of choline chloride nutrient pack, approximately 5 kg of calcium powder nutrient pack, approximately 1 kg of mineral nutrient pack, approximately 0.75 kg of magnesium chloride nutrient pack, and approximately 2 kg of potassium chloride nutrient pack. The base material for each nutrient pack is lactose.

[0155] Infant formula milk powder containing a combination of LNnT and probiotics 3 (prepared in 1000 kg batches):

[0156] 2100 kg raw milk, 280 kg lactose, 230 kg demineralized whey powder D90, 72 kg OPO structured lipids, 54 kg soybean oil, 9 kg corn oil, 45 kg high-oleic sunflower seed oil, 10 kg α-lactalbumin powder, 1 kg β-casein powder, 6 kg fructooligosaccharide powder, 22 kg galactooligosaccharide syrup, 3 kg soybean lecithin, 0.5 kg human milk oligosaccharide LNnT, 22.85 kg compound nutrients, 12 kg DHA, 14 kg ARA, 0.45 kg Bifidobacterium lactis BL-99, and 0.65 kg nucleotides.

[0157] The compound nutrients include approximately 1.5 kg of choline chloride, approximately 16 kg of calcium powder, approximately 1 kg of minerals, approximately 0.85 kg of magnesium chloride, and 3.5 kg of vitamins. The base of each nutrient pack is lactose.

[0158] The process is as follows:

[0159] 1) Coarse filtration of milk: After coarse filtration and degassing in a balance cylinder, the milk is preheated by a plate heat exchanger and then separated by a separator to remove impurities.

[0160] 2) Milk homogenization and sterilization: After removing impurities, part of the raw milk is homogenized in a homogenizer, while the other part is not homogenized. The two are then mixed and put into the sterilization system for sterilization.

[0161] 3) Powder addition: Various powder raw materials are metered according to the formula and added to the powder mixing tank through the pneumatic conveying system, and then sucked into the vacuum mixing tank through the vacuum system;

[0162] 4) Melting and blending oil: According to the formula requirements, put the oil specified in the formula into the melting room. The temperature of the melting room is maintained at 50~90℃. After the oil is melted, pump it into the mixed oil storage tank, and pump the mixed oil into the mixing tank through the oil pump according to the formula requirements.

[0163] 5) Nutrient dissolution and addition: Dissolve the calcium powder, vitamins, minerals and other nutrient packets separately in purified water, and then add them to the mixing tank in sequence to obtain a mixed liquid.

[0164] 6) LNnT dissolution and addition: After dissolving part of the LNnT raw material in the mixture from step 5, add it to the mixing tank to obtain a mixture containing LNnT.

[0165] 7) Filtration: The mixed liquid containing LNnT is filtered through a filter screen to remove physical impurities that may be introduced into the raw materials.

[0166] 8) Homogenization: The mixed liquid is homogenized by a homogenizer to mechanically process the fat globules and disperse them into uniform fat globules.

[0167] 9) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: it is cooled to below 20°C and temporarily stored in the pre-storage tank. It will enter the next process within 6 hours, and the agitator will be turned on according to the set requirements.

[0168] 10) Concentration and sterilization: Double-effect concentration is used during production, with a sterilization temperature ≥83℃ and a sterilization time of 25 seconds. The output concentration is 50% dry matter.

[0169] 11) Concentrated milk storage, preheating and filtration, and spray drying: The concentrated milk is temporarily stored in a concentrated milk balance tank. It is preheated to 60℃ by a scraper preheater. After preheating, the material is filtered through a 1mm pore size filter and then pumped into a drying tower for spray drying using a high-pressure pump. Fine powder agglomerates at the top of the tower or in a fluidized bed as required. Inlet air temperature: 180℃, outlet air temperature: 86℃, high-pressure pump pressure: 200 bar, tower negative pressure: approximately -4 mba.

[0170] 12) Fluidized bed drying and cooling: The powder coming out of the drying tower is dried again in a fluidized bed (primary stage) and then cooled to 30°C in a fluidized bed (secondary stage).

[0171] 13) Packaging: According to the formula requirements, the powder production workshop personnel weigh and seal the DHA, ARA, or Bifidobacterium longum subsp. GB1496 or Bifidobacterium lactis BL-99 for packaging.

[0172] 14) Dry mixing: Mix the weighed DHA, ARA or Bifidobacterium longum subsp. GB1496 with the milk powder in a dry mixer.

[0173] 15) Sieving: The milk powder is sieved to make the particle size uniform and the powder residue is disposed of as waste.

[0174] 16) Powder discharge: Collect powder in a sterilized powder collection box and transport it from the powder discharge room to the powder loading room.

[0175] 17) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0176] 18) Packaging: 400g automatic packaging machine with nitrogen filling. Oxygen content is less than 1% during nitrogen filling. 900g iron cans are automatically packaged with nitrogen filling and have an oxygen content of less than 5%.

[0177] 19) Packing: Put the packaged small bags into the carton and add the powder scoop at the same time, and seal the carton with a sealing machine.

[0178] 20) Finished product inspection: Sampling inspection of packaged products according to the inspection plan.

[0179] 21) Warehousing and storage: Products that have passed inspection shall be stored in the warehouse at room temperature with a humidity of ≤65%.

[0180] process parameters

[0181] 1) Milk collection section parameters

[0182]

[0183] 2) Pre-treatment section parameters

[0184]

[0185] 3) Concentration Section Parameters

[0186]

[0187] 4) Drying section parameters

[0188]

[0189] 5) Packaging parameters

[0190] 5.1) Dry-mix section

[0191]

[0192] 5.2) Packaging Section

[0193]

Claims

1. A formula milk powder, wherein, Based on a total weight of 1000 parts of formula milk powder, the raw materials for preparing the formula milk powder include: 0-4.5 parts of human milk oligosaccharides, 890-3800 parts of raw milk, 0-480 parts of lactose, 0-540 parts of demineralized whey powder, 0-350 parts of skim milk powder, 0-80 parts of whey protein powder (WPC80), 0-120 parts of whey protein powder (WPC34), 0-225 parts of vegetable oil, 0-45 parts of α-lactalbumin, 0-23 parts of β-casein, 1-2.5 parts of phospholipids, 0-30 parts of fructooligosaccharides, 0-90 parts of galactooligosaccharide syrup, 0-0.18 parts of probiotics, 0-5 parts of anhydrous butter, 0-0.8 parts of nucleotides, 1-5 parts of vitamin nutrients, 0-3 parts of choline chloride, 0-2 parts of mineral A, and mineral B. 1-12 parts by weight; wherein, mineral A is selected from a combination of one or more mineral salts selected from copper, iron, magnesium, zinc, selenium, manganese and iodine, and mineral B is selected from a combination of one or more mineral salts selected from calcium, phosphorus, sodium and potassium; the human milk oligosaccharide contains human milk oligosaccharide LNnT, and the human milk oligosaccharide LNnT is 0.01-4.5 parts by weight; the probiotics are selected from one or more combinations of Bifidobacterium infantis YLGB-1496 and Bifidobacterium lactis BL-99; the probiotic content is 10 per gram of formula milk powder. 6 -2×10 12 CFU.

2. The formula milk powder according to claim 1, wherein, The vegetable oil is selected from one or more combinations of structured oil OPO, high oleic sunflower seed oil, corn oil, low erucic acid rapeseed oil, and soybean oil. When each vegetable oil component exists independently, based on a total weight of 1000 parts of formula milk powder, the amounts of each vegetable oil component are as follows: structured oil OPO 0~170 parts by weight, high oleic sunflower seed oil 0~150 parts by weight, corn oil 0~50 parts by weight, low erucic acid rapeseed oil 0~50 parts by weight, and soybean oil 0~80 parts by weight.

3. The formula milk powder according to claim 1, wherein, The vitamin nutrients are selected from one or more combinations of vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinamide, folic acid, pantothenic acid and biotin.

4. The formula milk powder according to claim 1, wherein, The formula milk powder contains human milk oligosaccharide LNnT, with a content of 142.9-428.6 mg / 100g powder per 100g formula milk powder.

5. The formula milk powder according to claim 4, wherein, The content of human milk oligosaccharide (LNnT) is 178.6-392.9 mg / 100g of formula milk powder.

6. The formula milk powder according to claim 1, wherein, The probiotic content is 10 per gram of formula milk powder. 8 -2×10 10 CFU.

7. The formula milk powder according to any one of claims 1 to 6, wherein, The formula milk powder also includes the following ingredients: 0.20~2.04 parts by weight of inositol, 0~0.65 parts by weight of taurine, 0.06~0.5 parts by weight of L-carnitine, 3~18 parts by weight of DHA, and 3~22 parts by weight of ARA.

8. The formula milk powder according to any one of claims 1 to 6, wherein, The formula milk powder mentioned is an infant formula milk powder designed to reduce hydrogen sulfide in the intestines of infants and young children.

9. A method for preparing formula milk powder according to any one of claims 1 to 8, wherein, The method includes: wet batching – homogenization – concentration and sterilization – spray drying – dry mixing – packaging.

Images